These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8522632)

  • 1. Effects of phenytoin on plasma high-density lipoprotein cholesterol levels in men with low levels of high-density lipoprotein cholesterol.
    Goerdt C; Keith M; Rubins HB
    J Clin Pharmacol; 1995 Aug; 35(8):767-75. PubMed ID: 8522632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of low-dose phenytoin on high-density lipoprotein cholesterol.
    McKenney JM; Petrizzi KS; Briggs GC; Wright JT
    Pharmacotherapy; 1992; 12(3):183-8. PubMed ID: 1608850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol.
    Miller M; Burgan RG; Osterlund L; Segrest JP; Garber DW
    Arterioscler Thromb Vasc Biol; 1995 Dec; 15(12):2151-6. PubMed ID: 7489236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
    Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers. A randomized, controlled trial.
    Roeback JR; Hla KM; Chambless LE; Fletcher RH
    Ann Intern Med; 1991 Dec; 115(12):917-24. PubMed ID: 1683196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
    Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT
    Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of lipid phenotypes in community-living men with coronary heart disease. High prevalence of isolated low levels of high-density lipoprotein cholesterol.
    Rubins HB; Schectman G; Wilt TJ; Iwane MK
    Arch Intern Med; 1992 Dec; 152(12):2412-6. PubMed ID: 1456850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group.
    Wilt TJ; Rubins HB; Collins D; O'Connor TZ; Rutan GH; Robins SJ
    Arch Intern Med; 1996 Jun; 156(11):1181-8. PubMed ID: 8639012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Veterans Affairs HDL Intervention Trial.
    Papademetriou V; Narayan P; Rubins H; Collins D; Robins S
    Am Heart J; 1998 Oct; 136(4 Pt 1):734-40. PubMed ID: 9778079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study.
    Miller M; Bachorik PS; McCrindle BW; Kwiterovich PO
    Am J Med; 1993 Jan; 94(1):7-12. PubMed ID: 8420303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.
    J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
    Boden WE
    Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
    Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM
    Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hormone replacement therapy on serum lipids in elderly women. a randomized, placebo-controlled trial.
    Binder EF; Williams DB; Schechtman KB; Jeffe DB; Kohrt WM
    Ann Intern Med; 2001 May; 134(9 Pt 1):754-60. PubMed ID: 11329233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial.
    Gordon DJ; Knoke J; Probstfield JL; Superko R; Tyroler HA
    Circulation; 1986 Dec; 74(6):1217-25. PubMed ID: 3536151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.
    Bays HE; McKenney JM; Dujovne CA; Schrott HG; Zema MJ; Nyberg J; MacDougall DE;
    Am J Cardiol; 2003 Sep; 92(5):538-43. PubMed ID: 12943873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.